AU2022253455A1 - Combination therapies using prmt5 inhibitors for the treatment of cancer - Google Patents

Combination therapies using prmt5 inhibitors for the treatment of cancer Download PDF

Info

Publication number
AU2022253455A1
AU2022253455A1 AU2022253455A AU2022253455A AU2022253455A1 AU 2022253455 A1 AU2022253455 A1 AU 2022253455A1 AU 2022253455 A AU2022253455 A AU 2022253455A AU 2022253455 A AU2022253455 A AU 2022253455A AU 2022253455 A1 AU2022253455 A1 AU 2022253455A1
Authority
AU
Australia
Prior art keywords
alkyl
inhibitor
hydrogen
cancer
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022253455A
Other languages
English (en)
Inventor
James Gail CHRISTENSEN
Lars Daniel ENGSTROM
Peter Olson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mirati Therapeutics Inc
Original Assignee
Mirati Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics Inc filed Critical Mirati Therapeutics Inc
Publication of AU2022253455A1 publication Critical patent/AU2022253455A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022253455A 2021-04-08 2022-04-05 Combination therapies using prmt5 inhibitors for the treatment of cancer Pending AU2022253455A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163172639P 2021-04-08 2021-04-08
US63/172,639 2021-04-08
US202163252998P 2021-10-06 2021-10-06
US63/252,998 2021-10-06
PCT/US2022/023394 WO2022216648A1 (en) 2021-04-08 2022-04-05 Combination therapies using prmt5 inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
AU2022253455A1 true AU2022253455A1 (en) 2023-11-02

Family

ID=81748231

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022253455A Pending AU2022253455A1 (en) 2021-04-08 2022-04-05 Combination therapies using prmt5 inhibitors for the treatment of cancer

Country Status (9)

Country Link
US (2) US12128048B2 (https=)
EP (1) EP4319754A1 (https=)
JP (1) JP2024513492A (https=)
KR (1) KR20230167053A (https=)
AU (1) AU2022253455A1 (https=)
CA (1) CA3214530A1 (https=)
IL (1) IL307392A (https=)
MX (1) MX2023011856A (https=)
WO (1) WO2022216648A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022500385A (ja) * 2018-09-10 2022-01-04 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
EA202190749A1 (ru) * 2018-09-10 2021-07-09 Мирати Терапьютикс, Инк. Способы комбинированной терапии
US20240208912A1 (en) * 2021-03-11 2024-06-27 Mirati Therapeutics, Inc. MTA-Cooperative PRMT5 Inhibitors
WO2023098439A1 (zh) * 2021-11-30 2023-06-08 上海和誉生物医药科技有限公司 一种吡唑衍生物，其制备方法和在药学上的应用
WO2023125540A1 (zh) * 2021-12-27 2023-07-06 南京明德新药研发有限公司 吡唑-1(2h)-酞嗪酮类化合物及其应用
WO2023202626A1 (zh) * 2022-04-22 2023-10-26 北京望实智慧科技有限公司 稠和哒嗪酮化合物作为prmt5抑制剂
CN119301101A (zh) * 2022-07-29 2025-01-10 四川科伦博泰生物医药股份有限公司 甲基吡唑化合物、包含其的药物组合物及其制备方法和用途
WO2024027703A1 (zh) * 2022-08-02 2024-02-08 上海艾力斯医药科技股份有限公司 一种prmt5抑制剂、其制备方法及应用
CN120265615A (zh) * 2022-11-29 2025-07-04 正大天晴药业集团股份有限公司 含有二氢酞嗪的化合物
JP2026506429A (ja) * 2022-12-21 2026-02-25 アムジエン・インコーポレーテツド Ｍｔａ協同的ｐｒｍｔ５阻害薬を使用した癌治療
CN120712260A (zh) * 2023-02-21 2025-09-26 正大天晴药业集团股份有限公司 含有二氢酞嗪和烯基的化合物及其用途
WO2025157289A1 (zh) * 2024-01-26 2025-07-31 上海湃隆生物科技有限公司 包含prmt5抑制剂和krasg12c抑制剂的药物组合物
WO2025217015A1 (en) * 2024-04-08 2025-10-16 Mirati Therapeutics, Inc. Combination therapies using prmt5 inhibitors and kras g12d inhibitors for the treatment of cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102444509B1 (ko) 2016-05-18 2022-09-19 미라티 테라퓨틱스, 인크. Kras g12c 억제제
LT3710439T (lt) 2017-11-15 2023-05-10 Mirati Therapeutics, Inc. Kras g12c inhibitoriai
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
JP2021176819A (ja) * 2018-07-31 2021-11-11 アステラス製薬株式会社 キナゾリン化合物を有効成分とする医薬組成物
ES2961253T3 (es) 2018-08-31 2024-03-11 Mirati Therapeutics Inc Inhibidores de KRas G12C
EP3908283A4 (en) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
IL290341B2 (en) 2019-09-12 2024-11-01 Mirati Therapeutics Inc Mta-cooperative prmt5 inhibitors
KR20220086628A (ko) 2019-10-22 2022-06-23 루핀 리미티드 Prmt5 저해제의 약학적 조합물

Also Published As

Publication number Publication date
US20240423987A1 (en) 2024-12-26
US20220331324A1 (en) 2022-10-20
JP2024513492A (ja) 2024-03-25
KR20230167053A (ko) 2023-12-07
IL307392A (en) 2023-12-01
MX2023011856A (es) 2024-01-08
WO2022216648A1 (en) 2022-10-13
US12128048B2 (en) 2024-10-29
CA3214530A1 (en) 2022-10-13
EP4319754A1 (en) 2024-02-14

Similar Documents

Publication Publication Date Title
US12128048B2 (en) Combination therapies using PRMT5 inhibitors for the treatment of cancer
US12171765B2 (en) Combination therapies using PRMT5 inhibitors for the treatment of cancer
US12527795B2 (en) Compositions of adagrasib and mTOR inhibitors and methods of treatment therewith
EP3849537B1 (en) Combination therapies
AU2022361380A1 (en) Combination therapies of kras g12d inhibitors with sos1 inhibitors
US20240398795A1 (en) Combination therapies using prmt5 inhibitors for the treatment of cancer
AU2023334579A1 (en) Combination therapies using prmt5 inhibitors and bcl-2 family inhibitors for the treatment of cancer
WO2025217015A1 (en) Combination therapies using prmt5 inhibitors and kras g12d inhibitors for the treatment of cancer
WO2025217007A1 (en) Combination therapies using prmt5 inhibitors and immune checkpoint inhibitors for the treatment of cancer
WO2025217008A1 (en) Combination therapies using prmt5 inhibitors and sos1 inhibitors for the treatment of cancer
CN117769421A (zh) 使用prmt5抑制剂治疗癌症的组合疗法
CN117769420A (zh) 使用prmt5抑制剂治疗癌症的组合疗法
EA051338B1 (ru) Комбинированная терапия с использованием ингибиторов prmt5 для лечения рака